Compare FATE & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FATE | BNTC |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.0M | 307.7M |
| IPO Year | 2013 | 2020 |
| Metric | FATE | BNTC |
|---|---|---|
| Price | $2.07 | $9.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $5.74 | ★ $23.29 |
| AVG Volume (30 Days) | ★ 1.1M | 164.8K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $7.89 |
| 52 Week High | $3.23 | $14.39 |
| Indicator | FATE | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 38.37 |
| Support Level | $1.78 | $8.26 |
| Resistance Level | $2.15 | $9.29 |
| Average True Range (ATR) | 0.13 | 0.57 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 60.42 | 36.65 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.